Table 2.
Diagnostic performance of ELISPOT results in active TB patients, LTBI and healthy control groups
| Control median (IQR) | LTBI median (IQR) | Active TBI median (IQR) | P value control vs. active TB | P value LTBI vs. active TB | Area under the curve | Cutoff | Sensitivity% | Specificity% | |
|---|---|---|---|---|---|---|---|---|---|
| IFN-γ ELISPOT result* | |||||||||
| ESAT-6/CFP-10 | 25 (15-40) | 265 (190-333) | 275 (190-368) | 0.001 | 0.65 | 0.532 | 65 | 33.3 | 84.8 |
| AlaDH | 20 (15-25) | 85 (65-130) | 105 (78-150) | 0.001 | 0.11 | 0.612 | 245 | 48.5 | 63.6 |
| IL-2 ELISPOT result* | |||||||||
| ESAT-6/CFP-10 | 45 (35-65) | 200 (130-310) | 180 (138-323) | 0.001 | 0.93 | 0.494 | 235 | 69.7 | 42.4 |
| AlaDH | 25 (15-38) | 380 (270-580) | 185 (103-270) | 0.001 | 0.0001 | 0.820 | 275 | 75.8 | 78.8 |
ELISPOT: Enzyme-linked immunospot assay; TBI: Tuberculosis infection; LTBI: Latent tuberculosis infection;
*
Results are illustrated as medians and interquartile ranges of spot forming colonies per million peripheral blood mononuclear cells (PBMCs)